Literature DB >> 12970299

Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.

Carsten Boltze1, Jochen Mundschenk, Nicole Unger, Regine Schneider-Stock, Brigitte Peters, Christian Mawrin, Cuong Hoang-Vu, Albert Roessner, Hendrik Lehnert.   

Abstract

Telomerase, a ribonucleoprotein complex that includes the telomerase RNA component, the telomerase-associated protein (TP1), the telomerase catalytic subunit (hTERT), and the heat shock protein 90 (HSP90), is closely related to the malignant potential of human tumors. In pheochromocytomas (PC) it is very difficult to predict malignant potential by conventional histology or immunohistochemical and molecular markers. To test whether the expression of telomerase subunits is reflected in the malignant transition of PCs, we determined their mRNA and/or protein expression in 28 benign and nine malignant PCs and compared the results with telomerase activity. RT-PCR analysis revealed that TP1 was ubiquitously expressed. The telomerase RNA component was found in all malignant (100%) and in 13 of 28 (46%) benign PCs. In contrast, hTERT was clearly associated with aggressive biological behavior. All of the malignant (100%), but only two of 28 benign (7%) PCs expressed hTERT. HSP90 was increased in malignant PCs, but was also expressed at a lower level in benign tumors. High telomerase activity was measurable in hTERT-positive tissues only. Our data indicate that hTERT, HSP90, and telomerase activity are up-regulated in malignant cells of the adrenal medulla. The common expression of hTERT and telomerase activity thus represents an additional prognostic marker that may identify more aggressive tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970299     DOI: 10.1210/jc.2002-021299

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 2.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

Review 3.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

Review 4.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

5.  N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.

Authors:  Helena Leijon; Tuomas Kaprio; Annamari Heiskanen; Tero Satomaa; Jukka O Hiltunen; Markku M Miettinen; Johanna Arola; Caj Haglund
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

Review 6.  New developments in the detection of the clinical behavior of pheochromocytomas and paragangliomas.

Authors:  Ronald R de Krijger; Francien H van Nederveen; Esther Korpershoek; Winand N M Dinjens
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 7.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

8.  Carcinoma-like nonfunctional pheochromocytoma in the right adrenal gland: A case report.

Authors:  Shingo Moriyama; Hideki Takeshita; Saori Araki; Takuo Tokairin; Makoto Kagawa; Koji Chiba; Akiko Adachi; Akira Noro
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

Review 9.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

10.  Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.

Authors:  Gabriele Parenti; Benedetta Zampetti; Elena Rapizzi; Tonino Ercolino; Valentino Giachè; Massimo Mannelli
Journal:  J Oncol       Date:  2012-07-17       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.